Viralytics on track with IV delivery
Wednesday, 25 June, 2008
Viralytics (ASX: VLA) has completed the first step of phase I clinical trials of its oncolytic virus technology, Cavatrak, for stage IV metastatic melanoma.
The safety trial involved each subject receiving an intravenous injection of Cavatrak. No adverse effects were found in the test subjects, the company said.
Viralytics has also been granted clearance to continue the trials with the next patient group. This cohort will receive two injections of the drug seven days apart.
This trial is being run concurrently with another set of clinical trials of late-stage melanoma patients. The subjects in that trial are being given multiple intra-tumoural injections of Cavatrak in doses up to 100 times the original.
TGA acts on melatonin imports with infringement notices totalling $99K
Laboratory testing of several imported unregistered melatonin products has confirmed them to be...
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
